Myalepta (metreleptin): inconsistencies in the package leaflet
About
This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.
Documents
-
List item
Direct healthcare professional communication (DHPC): Myalepta (metreleptin) 5.8mg vial: inconsistency in the Spanish language package leaflet (PDF/285.44 KB)
First published: 18/06/2020
Dissemination date: 18/06/2020 -
List item
Direct healthcare professional communication (DHPC): Myalepta (metreleptin) 5.8 mg vial: inconsistency in the Portuguese-language package leaflet (PDF/300.99 KB)
First published: 18/06/2020
Dissemination date: 18/06/2020 -
List item
Direct healthcare professional communication (DHPC): Myalepta (metreleptin) 3 mg vial: inconsistency in the Portuguese-language package leaflet (PDF/355.26 KB)
First published: 18/06/2020
Dissemination date: 18/06/2020 -
List item
Direct healthcare professional communication (DHPC): Myalepta (metreleptin) 3 mg vial: inconsistency in the Spanish language package leaflet (PL) (PDF/303.48 KB)
First published: 18/06/2020
Dissemination date: 18/06/2020 -
List item
Direct healthcare professional communication (DHPC): Myalepta (metreleptin) 5.8 mg vial: inconsistency in the English-language package leaflet (PL) (PDF/239.04 KB)
First published: 18/06/2020
Dissemination date: 18/06/2020
Key facts
| Medicine name |
Myalepta
|
| Active substance |
Metreleptin
|
| Therapeutic area (MeSH) |
Lipodystrophy, Familial Partial
|
| Procedure number |
EMEA/H/C/004218
|
| DHPC type |
Quality defect
|
| Human ATC code |
A16AA
|
| Dissemination date |
18/06/2020
|